Recent studies into retatritide peptide highlight significant outlook for addressing excess body and type 2 diabetes. The molecule, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, appears to present improved weight loss and glycemic control versus existing treatments. Ongoing clinical trials are required to fully assess it